Neurogene (NGNE) Other Non Operating Income (2013 - 2026)
Neurogene (NGNE) reported Other Non Operating Income of $163000.0 for Q1 2026, up 10.14% on a YoY basis from $148000.0 in Q1 2025, and up 4.49% quarter-over-quarter from $156000.0 in Q4 2025.
Neurogene (NGNE) Other Non Operating Income (2013 - 2026) Analysis & Trends
Neurogene has reported Other Non Operating Income for 12 years, with the latest figure at $163000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Non Operating Income rose 10.14% year-over-year to $163000.0; the trailing twelve-month figure through Mar 2026 stood at $1.7 million (up 190.16% YoY), and the FY2025 full-year result was $1.7 million, up 190.07% from the prior year.
- Other Non Operating Income for Q1 2026 stood at $163000.0, up from $156000.0 in the prior quarter.
- The five-year high for Other Non Operating Income was $16.4 million in Q4 2023, with the low at $143000.0 in Q1 2024.
- Historically, Other Non Operating Income has averaged $1.9 million across 4 years, with a median of $148500.0 in 2025.
- Annual changes were most pronounced in 2024 — Other Non Operating Income tumbled 99.12% — and 2025, when it surged 741.67%.
- Neurogene's Other Non Operating Income stood at $16.4 million in 2023, then plunged by 99.12% to $144000.0 in 2024, then climbed by 8.33% to $156000.0 in 2025, then gained by 4.49% to $163000.0 in 2026.
- The last three Other Non Operating Income figures came in at $163000.0 (Q1 2026), $156000.0 (Q4 2025), and $149000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Neurogene | 216.17 Mn | 216.17 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 163,000.00 |
| Dec 31, 2025 | 156,000.00 |
| Sep 30, 2025 | 149,000.00 |
| Jun 30, 2025 | 1.21 Mn |
| Mar 31, 2025 | 148,000.00 |
| Dec 31, 2024 | 144,000.00 |
| Sep 30, 2024 | 143,000.00 |
| Jun 30, 2024 | 144,000.00 |
| Mar 31, 2024 | 143,000.00 |
| Dec 31, 2023 | 16.36 Mn |
| Mar 31, 2020 | 15,000.00 |
| Mar 31, 2019 | 2,000.00 |
| Dec 31, 2018 | 1.08 Mn |
| Sep 30, 2018 | -262,000.00 |
| Jun 30, 2018 | -118,000.00 |
| Mar 31, 2018 | -1,000.00 |
| Dec 31, 2017 | 976,000.00 |
| Sep 30, 2017 | 8,000.00 |
| Jun 30, 2017 | -9,000.00 |
| Mar 31, 2017 | -8,000.00 |